Loperamide 1980s, prior to the expiration of US patent on 30 January 1990, McNeil company started to develop Imodium Advanced containing loperamide and simethicone for treating both diarrhea and gas. In March 1997, the company patented such combination. The drug was approved in June 1997 by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet. In November 1993, loperamide was launched as an orally disintegrating tablet based on Zydis technology. Imodium Instant Melts from Johnson & Johnson is currently the only loperamide available in the form of orally disintegrating tablets. In 2013, loperamide in the form of
Intention-to-treat analysis be providing benefits if one merely compares the condition before and after the treatment for only those who finish the study (ignoring those who were enrolled originally, but have since been excluded or dropped out). Medical investigators often have difficulties in completing ITT analysis because of clinical trial issues like missing data or poor treatment protocol adherence. To address some of these issues, many clinical trials have excluded participants after the random assignment in their analysis, which is often referred to as "modified intention-to-treat analysis" or mITT. Trials employing mITT have been linked to industry sponsorship and conflicts of interest